Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Judy Kim

Retina Specialist Dallas, TX Medical Doctor

NPI 1992756746 CMS profile 180764

5303 Harry Hines Blvd Fl 6, Dallas, TX 75390

Open in the dashboard

General payments

$255,720

195 records reported · program years 2019–2025

Research payments

$21,437

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Judy Kim of Dallas, TX is reported in the CMS Open Payments database as having received $255,720 across 195 general payments and $21,437 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,690 28
2025 Research $2,065 4
2024 General $39,040 40
2024 Research $8,384 9
2023 General $35,803 32
2023 Research $10,987 4
2022 General $60,851 40
2021 General $19,984 13
2020 General $12,593 10
2019 General $44,760 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Judy Kim
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Judy Kim were reported at $42,690. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Judy Kim Retina Specialist median Middle half National median
2019 $44,760 $410 $157–$1,517 $163
2020 $12,593 $168 $65–$778 $114
2021 $19,984 $258 $101–$1,161 $132
2022 $60,851 $418 $162–$1,488 $149
2023 $35,803 $476 $178–$1,312 $160
2024 $39,040 $520 $188–$1,372 $164
2025 $42,690 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Apellis Pharmaceuticals, Inc. $29,577 20 payments
  2. Novartis Pharmaceuticals Corporation $27,394 9 payments
  3. Alcon Vision LLC $26,866 21 payments
  4. Genentech USA, Inc. $25,568 24 payments
  5. Genentech, Inc. $23,674 19 payments
  6. Regeneron Pharmaceuticals, Inc. $21,989 22 payments
  7. Allergan Inc. $15,719 17 payments
  8. Dutch Ophthalmic, USA $15,276 6 payments
  9. Bausch & Lomb Americas Inc. $11,861 7 payments
  10. F. Hoffmann-La Roche AG $9,110 3 payments
  11. Other $48,685 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $204,506 75 payments
  2. Travel and Lodging $16,943 34 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,739 2 payments
  4. Honoraria $9,075 4 payments
  5. Food and Beverage $6,438 78 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $4,000 1 payment
  7. Gift $19 1 payment
Products named General payments · program years 2019–2025
  1. BEOVU $27,394 9 payments
  2. Syfovre $19,376 16 payments
  3. EYLEA $17,901 18 payments
  4. UNITY $16,017 10 payments
  5. EVA, combined machine $12,905 4 payments
  6. EYLEA HD $12,534 10 payments
  7. VABYSMO $12,431 13 payments
  8. Constellation $11,988 7 payments
  9. SUSVIMO $11,593 13 payments
  10. NGENUITY $10,080 7 payments
  11. Other $110,627 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $18,112 12 payments
  2. Regeneron Pharmaceuticals, Inc. $2,065 4 payments
  3. Genentech, Inc. $1,260 1 payment

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$12,906

Medicare's payments for the services billed

Medicare patients

26

Average age 71

Services billed

102

13 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 50%
Diabetes 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Syfovre
  • Apellis Pharmaceuticals, Inc. $17,657
$17,657 — —
Xolair
  • Genentech USA, Inc. $8,562
$8,562 — —
PAVBLU
  • Amgen Inc. $4,915
$4,915 — —
EYLEA HD
  • Regeneron Pharmaceuticals, Inc. $1,233
$1,233 — —
EYLEA
  • Regeneron Pharmaceuticals, Inc. $1,109
$1,109 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record